Drug intelligence / Profile preview

Human papillomavirus vaccine recombinant pentavalent

Development stage: Phase 2
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

Human papillomavirus vaccine recombinant pentavalent (V504) is a pentavalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine developed for the prevention of infection by various HPV types. Upon administration, it generates humoral immunity against several HPV L1 major capsid proteins, thereby preventing cervical and other HPV-related infections. The primary indication is the prevention of diseases caused by specific oncogenic and non-oncogenic HPV types. The developer is Merck[1][2].

Other names: HPV L1 VLP vaccine V504human papilloma virus L1 virus-like particle (V504) vaccine

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on Human papillomavirus vaccine recombinant pentavalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human papillomavirus vaccine recombinant pentavalent.